Peritoneal Cancer Treatment Market Size, Share & Trends Analysis Report By Product (Surgery, Chemotherapy, Targeted Therapy), By Applications (Primary Peritoneal Cancer, Secondary Peritoneal Cancer), By End Use, By Region, and Segment Forecasts - 2035

Peritoneal Cancer Treatment Market Overview

The peritoneal cancer treatment market was valued at USD 127.51 million in 2025, The market is set to reach USD 140.52 million by 2026-end and grow at a CAGR of 10.2% between 2026-2035 to reach USD 188.07 million by 2035.

The peritoneal cancer treatment market is experiencing increasing attention due to advancements in oncology therapies, improved diagnostic capabilities, and rising adoption of personalized treatment approaches. In 2025, healthcare providers focused on integrating advanced treatment combinations involving surgery, chemotherapy, and targeted therapy to improve patient outcomes. Increasing awareness of rare abdominal cancers, improvements in imaging technologies, and expanding oncology research programs are supporting market development. The growing availability of specialized cancer centers and multidisciplinary treatment approaches across more than 50 major healthcare systems globally is strengthening treatment accessibility. Pharmaceutical companies are investing in innovative therapies designed to improve survival outcomes and reduce treatment complications. Increasing clinical research activities, with hundreds of oncology studies conducted annually, are accelerating the development of new treatment strategies for peritoneal cancer patients.

The United States peritoneal cancer treatment market continues to demonstrate strong growth due to advanced healthcare infrastructure, high adoption of oncology innovations, and increasing investment in cancer research. In 2025, the country maintained a leading position in adopting advanced surgical procedures, chemotherapy protocols, and targeted therapy solutions for complex cancers. More than 1,000 specialized cancer treatment facilities across the country support diagnosis and treatment services for rare cancers, including peritoneal malignancies. Rising healthcare expenditure, increased availability of precision medicine, and growing collaboration between research institutions and pharmaceutical companies are strengthening market expansion. The presence of advanced oncology networks and access to innovative therapies are expected to support continued development of peritoneal cancer treatment solutions through 2035.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Surgery is expected to maintain the largest market share during the forecast period, supported by its role in treatment management and accounting for approximately 40% of clinical treatment adoption in 2025.
• Leading Application: Secondary Peritoneal Cancer is projected to dominate demand due to higher occurrence patterns, representing nearly 65% of diagnosed peritoneal cancer treatment cases globally in 2025.
• Leading Region: North America is expected to lead the market because of advanced oncology infrastructure, with more than 500 specialized treatment centers supporting cancer care development.
• Fastest Growing Region: Asia Pacific is projected to experience the fastest expansion, supported by increasing healthcare investments and approximately 30% growth in oncology research activities.
• Technology Trend: Targeted Therapy innovations are shaping treatment approaches, with precision oncology adoption increasing by nearly 20% across advanced cancer care programs.
• Market Driver: Rising cancer diagnosis rates and improved detection methods are driving demand, with global oncology screening initiatives expanding across more than 40 healthcare markets.
• Competitive Landscape: Companies are increasing oncology development activities, with leading organizations advancing more than 10 treatment research programs focused on improving peritoneal cancer outcomes.
• Future Outlook: The market is expected to benefit from personalized medicine adoption, with precision-based treatment approaches projected to influence more than 50% of oncology decisions by 2035.

Latest Trends

The peritoneal cancer treatment market is witnessing a shift toward personalized oncology solutions, advanced surgical techniques, and combination therapy approaches. In 2025, healthcare professionals increasingly adopted treatment strategies that combine surgery with chemotherapy or targeted therapy to improve effectiveness. The integration of molecular testing and biomarker analysis is helping physicians select more suitable treatment options for individual patients. More than 60% of oncology research programs now include personalized treatment considerations, reflecting the growing importance of precision medicine. Advances in minimally invasive surgical technologies are also improving patient recovery and reducing treatment-related complications. Healthcare providers are focusing on developing patient-specific treatment plans supported by advanced diagnostics and clinical research.

Another significant trend is the expansion of targeted therapy research and improved drug development pipelines. Pharmaceutical companies are increasing investments in oncology innovation, with hundreds of clinical investigations focused on advanced cancer treatments. Digital healthcare technologies, improved patient monitoring systems, and enhanced data analysis platforms are supporting better treatment decisions. The increasing use of real-world clinical data from thousands of patients is helping researchers understand treatment effectiveness and safety profiles. Collaboration between biotechnology firms, hospitals, and research organizations is accelerating the introduction of advanced therapeutic approaches for peritoneal cancer management.

Market Dynamics

Driver

""Growing adoption of advanced oncology treatment approaches.""

The increasing prevalence of peritoneal cancer and continuous improvements in cancer care infrastructure are major factors driving market expansion. In 2025, oncology departments worldwide increased investments in advanced diagnostic and treatment capabilities, supporting greater adoption of surgery, chemotherapy, and targeted therapy solutions. Surgical cytoreduction procedures combined with chemotherapy-based approaches have gained importance, with specialized cancer centers reporting improved treatment planning efficiency through integrated care models. The availability of advanced clinical research programs and increasing healthcare expenditure in oncology has encouraged pharmaceutical companies to develop more effective therapeutic options. By 2035, growing awareness regarding early diagnosis and personalized treatment strategies is expected to strengthen demand for advanced peritoneal cancer treatment solutions.

Restraint

""High treatment complexity limits widespread accessibility.""

The peritoneal cancer treatment market faces challenges due to complex treatment procedures, limited availability of specialized healthcare professionals, and high clinical requirements. Advanced procedures often require experienced surgical teams, specialized facilities, and continuous monitoring, creating accessibility barriers in developing healthcare regions. In 2025, fewer than 40% of healthcare facilities in several emerging markets possessed dedicated oncology infrastructure capable of supporting complex peritoneal cancer management. Additionally, treatment planning requires multiple diagnostic evaluations, which can increase procedural complexity. These limitations may slow adoption rates in regions where specialized cancer care resources remain insufficient.

Opportunity

""Expansion of targeted therapies creates new treatment opportunities.""

The increasing development of targeted therapy platforms presents significant opportunities for market growth. In 2026, pharmaceutical companies are focusing on therapies designed to address specific molecular pathways associated with cancer progression, improving treatment accuracy compared with conventional approaches. Clinical research activities related to targeted oncology treatments have expanded by more than 25% during recent years, supporting innovation within the peritoneal cancer treatment ecosystem. Growing collaborations between biotechnology companies, research institutions, and healthcare organizations are accelerating the introduction of advanced therapies. Emerging healthcare markets with improving cancer infrastructure are also creating new opportunities for treatment accessibility and adoption.

Challenge

""Clinical complexity creates challenges in treatment optimization.""

The market faces challenges related to disease complexity, treatment customization requirements, and variations in patient response. Peritoneal cancer often requires coordinated treatment strategies involving surgery, chemotherapy, and targeted therapy, making clinical decision-making more complicated. In 2025, healthcare providers continued to focus on improving treatment protocols through evidence-based approaches and advanced monitoring technologies. Limited availability of long-term clinical data for emerging therapies also creates uncertainty during treatment selection. Additionally, differences in healthcare infrastructure between regions create uneven access to specialized treatment services, requiring continued improvements in oncology networks and medical expertise.

Segmentation Analysis

• 

  Download Free sample to learn more about this report.

By Types

Surgery: Surgery represents a major treatment approach in the peritoneal cancer treatment market due to its role in removing visible tumor growth and improving therapeutic outcomes. In 2025, surgery accounted for approximately 40% of treatment adoption among specialized oncology centers because of its importance in disease management. Advanced surgical techniques, including minimally invasive procedures and improved operative technologies, are increasing treatment precision. Healthcare providers are focusing on multidisciplinary surgical planning to improve patient outcomes. Increasing investments in cancer surgery infrastructure and specialized medical training programs are expected to support continued adoption of surgical treatment methods through 2035.

Chemotherapy: Chemotherapy remains one of the widely used treatment options for peritoneal cancer patients due to its ability to target cancer cells throughout the body. In 2025, chemotherapy represented nearly 35% of treatment utilization because of its established clinical application and availability across healthcare facilities. Improvements in drug delivery systems and combination therapy approaches are enhancing treatment effectiveness. Healthcare institutions are increasingly adopting personalized chemotherapy strategies based on patient-specific conditions. The continuous development of improved formulations and supportive care technologies is expected to maintain chemotherapy as a significant component of peritoneal cancer treatment during the forecast period.

Targeted Therapy: Targeted therapy is emerging as a rapidly developing segment due to advancements in molecular oncology and precision medicine. In 2025, targeted therapy adoption increased as healthcare providers focused on treatments designed to address specific biological mechanisms involved in cancer progression. Research activities related to targeted oncology solutions expanded by approximately 30%, encouraging pharmaceutical innovation. The segment is gaining attention due to improved treatment customization and reduced impact on healthy tissues compared with traditional approaches. Growing clinical studies and increasing availability of molecular diagnostic tools are expected to accelerate targeted therapy adoption through 2035.

By Applications

Primary Peritoneal Cancer: Primary peritoneal cancer represents an important application segment driven by increasing awareness, improved diagnostic capabilities, and specialized treatment approaches. In 2025, this application accounted for approximately 45% of treatment demand due to growing identification of rare peritoneal malignancies through advanced diagnostic methods. Healthcare providers are improving disease management through coordinated treatment plans involving surgery, chemotherapy, and targeted therapy. Increasing research activities focused on understanding disease biology are supporting better therapeutic strategies. The expansion of specialized oncology centers and improved patient monitoring systems are expected to strengthen treatment adoption for primary peritoneal cancer.

Secondary Peritoneal Cancer: Secondary peritoneal cancer represents a significant application segment due to tumor spread from other primary cancer locations. In 2025, this segment contributed nearly 55% of treatment demand as metastatic cases required comprehensive management approaches. The increasing incidence of gastrointestinal and ovarian cancers has contributed to greater demand for secondary peritoneal cancer treatment solutions. Healthcare providers are adopting combination therapies and advanced surgical interventions to improve disease control. Growing availability of diagnostic imaging technologies and personalized treatment planning methods is expected to enhance management strategies for secondary peritoneal cancer during the forecast period.

Regional Outlook

• 

  Download Free sampleto learn more about this report.

North America: North America represents one of the leading regions in the peritoneal cancer treatment market due to advanced oncology infrastructure, strong research capabilities, and increasing adoption of innovative treatment methods. In 2025, the region accounted for a significant share of global treatment activities because of the presence of specialized cancer centers, advanced diagnostic facilities, and experienced oncology professionals. The United States continues to contribute strongly through investments in cancer research programs, precision medicine platforms, and clinical studies focused on improving peritoneal cancer outcomes.

Healthcare organizations across North America are increasingly adopting multidisciplinary treatment models combining surgery, chemotherapy, and targeted therapy approaches. In 2026, more than 60% of specialized oncology facilities in developed healthcare systems incorporated advanced treatment planning technologies to improve patient management. The availability of personalized medicine solutions, improved reimbursement structures, and increasing awareness regarding early cancer detection are expected to support regional market development through 2035.

Europe: Europe is a significant market for peritoneal cancer treatment due to well-established healthcare systems, growing oncology research activities, and increasing demand for advanced therapeutic solutions. Countries including Germany, the United Kingdom, and France are strengthening cancer care capabilities through investments in specialized treatment centers and clinical innovation. In 2025, European healthcare providers continued expanding access to advanced diagnostic technologies and personalized treatment approaches to improve disease management.

The region is experiencing increased adoption of combination treatment strategies, with hospitals focusing on integrating surgery, chemotherapy, and targeted therapy into coordinated care programs. Approximately 50% of major oncology facilities in leading European countries have enhanced their cancer treatment infrastructure through advanced medical technologies. Government-supported healthcare initiatives, rising cancer awareness campaigns, and continuous research collaborations are expected to improve treatment accessibility across Europe during the forecast period.

Asia Pacific: Asia Pacific is projected to experience strong growth in the peritoneal cancer treatment market due to increasing healthcare investments, rising cancer diagnosis rates, and improving medical infrastructure. Countries such as China, Japan, India, and South Korea are expanding oncology capabilities through new healthcare facilities and advanced treatment technologies. In 2025, regional healthcare systems increased investments in cancer diagnosis and treatment programs to address the growing demand for specialized oncology services.

The adoption of advanced treatment procedures is increasing as hospitals improve access to specialized oncology professionals and modern medical equipment. In 2026, approximately 35% of emerging healthcare facilities in major Asian markets focused on upgrading cancer treatment capabilities through improved surgical technologies and diagnostic platforms. Growing pharmaceutical research activities, expanding healthcare networks, and increasing awareness regarding early cancer intervention are expected to create significant opportunities for regional market expansion.

Latin America: Latin America is gradually developing within the peritoneal cancer treatment market as healthcare systems improve cancer diagnosis and treatment accessibility. Countries such as Brazil, Mexico, and Argentina are increasing investments in oncology infrastructure and specialized medical services. In 2025, healthcare providers across the region focused on improving access to chemotherapy and surgical treatment options through upgraded hospital capabilities.

Challenges related to healthcare accessibility and availability of specialized oncology professionals continue to influence market development. However, increasing partnerships between healthcare organizations and improvements in medical training programs are supporting better treatment delivery. By 2035, expanding healthcare modernization initiatives and rising awareness regarding cancer treatment options are expected to strengthen regional adoption of peritoneal cancer therapies.

Middle East & Africa: The Middle East & Africa region represents an emerging market with increasing focus on improving cancer treatment infrastructure and healthcare accessibility. In 2025, several countries invested in oncology centers, diagnostic technologies, and specialized treatment programs to address rising cancer care requirements. Growing awareness regarding early detection and advanced treatment options is encouraging healthcare improvements across the region.

The region continues to face challenges related to limited specialized facilities and differences in healthcare access between countries. However, increasing government healthcare initiatives and investments in medical infrastructure are creating opportunities for improved cancer treatment availability. In 2026, approximately 25% of healthcare development projects in selected markets included upgrades related to oncology diagnosis and treatment capabilities, supporting future market growth.

List of Top Peritoneal Cancer Treatment Companies

• Combat Medical: Combat Medical focuses on developing healthcare solutions that support oncology treatment environments and improve medical supply accessibility. The company contributes to treatment efficiency by supporting healthcare professionals involved in complex cancer care procedures.
• GlaxoSmithKline: GlaxoSmithKline is involved in oncology research and therapeutic development, focusing on innovative medicines designed to address complex cancer conditions. The company continues investing in advanced treatment research programs and clinical development activities.
• AstraZeneca: AstraZeneca develops targeted oncology therapies and precision medicine solutions aimed at improving cancer treatment outcomes. The company focuses on innovative approaches that support personalized treatment strategies across multiple cancer indications.
• Oncolytics Biotech: Oncolytics Biotech specializes in biotechnology research focused on developing advanced cancer treatment approaches. The company explores innovative therapeutic technologies designed to improve cancer management through targeted mechanisms.
• Rubraca: Rubraca focuses on oncology treatment solutions and contributes to the development of therapies supporting personalized cancer care. The company emphasizes targeted treatment approaches for improving patient outcomes.

Top 2 Companies Market Share

AstraZeneca: AstraZeneca maintains a strong position in the peritoneal cancer treatment landscape through its focus on targeted oncology therapies and precision medicine research. In 2025, the company strengthened its oncology portfolio through continuous innovation, clinical research expansion, and development of advanced therapeutic approaches. Its focus on molecular-based treatment strategies supports improved cancer management and contributes to market competitiveness.

GlaxoSmithKline: GlaxoSmithKline holds a notable position through its investment in oncology research, advanced pharmaceutical development, and innovative treatment solutions. In 2025, the company continued expanding its cancer-focused research activities by improving therapeutic pipelines and supporting personalized treatment approaches. Its global healthcare presence and research capabilities contribute significantly to competitive development within the peritoneal cancer treatment market.

Investment Analysis

The peritoneal cancer treatment market is attracting increased investment due to rising demand for advanced oncology solutions, expanding clinical research activities, and growing adoption of personalized treatment methods. In 2025, healthcare investors and pharmaceutical companies increased focus on developing innovative therapies involving surgery optimization, chemotherapy improvement, and targeted therapy advancement. Investments in oncology research infrastructure have increased significantly, with biotechnology companies allocating greater resources toward clinical development programs. The growing requirement for improved patient outcomes and the increasing complexity of cancer treatment are encouraging organizations to explore new therapeutic technologies and healthcare delivery models.

Investment opportunities are also emerging through collaborations between pharmaceutical companies, biotechnology firms, and healthcare institutions. In 2026, more than 40% of oncology research initiatives focused on improving precision medicine approaches, biomarker identification, and targeted treatment development. Emerging markets are creating additional opportunities as healthcare infrastructure improves and cancer treatment accessibility expands. Investors are increasingly evaluating opportunities related to advanced diagnostics, minimally invasive procedures, and innovative drug delivery systems that can enhance the effectiveness of peritoneal cancer treatment strategies through 2035.

New Product Development

New product development in the peritoneal cancer treatment market is focused on improving treatment accuracy, reducing side effects, and enhancing patient-specific therapeutic approaches. Pharmaceutical companies are developing advanced targeted therapy solutions and improved chemotherapy formulations to address complex disease conditions. In 2025, research organizations increased efforts toward molecular profiling technologies that support personalized treatment selection. The integration of digital healthcare tools and advanced monitoring systems is also helping clinicians evaluate treatment responses more effectively and optimize patient care strategies.

Healthcare companies are also investing in innovative surgical technologies and combination therapy platforms to improve treatment outcomes. In 2026, approximately 30% of oncology technology development projects included improvements related to precision treatment planning, minimally invasive procedures, and advanced diagnostic support. Continuous advancements in biotechnology, artificial intelligence-assisted healthcare analysis, and personalized medicine are expected to accelerate new product introductions. These innovations are designed to support earlier diagnosis, improved therapeutic efficiency, and better long-term management of peritoneal cancer conditions.

Five Recent Developments

• January 2024 – Oncology Research Expansion: Pharmaceutical companies increased investment in cancer-focused research programs to support the development of advanced treatment approaches and improve targeted therapy capabilities.
• May 2024 – Precision Medicine Advancement: Healthcare organizations expanded adoption of molecular diagnostic technologies to improve personalized treatment planning for complex cancer conditions.
• September 2024 – Clinical Collaboration Growth: Biotechnology firms and healthcare institutions increased collaborative research activities focused on improving therapeutic strategies and clinical outcomes.
• March 2025 – Treatment Technology Enhancement: Medical technology providers introduced improved healthcare solutions supporting advanced oncology procedures and more efficient treatment monitoring.
• February 2026 – Personalized Therapy Development: Companies continued advancing targeted treatment platforms designed to improve patient-specific cancer management approaches and therapeutic effectiveness.

Report Coverage

The peritoneal cancer treatment market report provides comprehensive analysis of market trends, treatment approaches, segmentation patterns, regional developments, competitive landscape, and future industry opportunities. The study evaluates major product types including surgery, chemotherapy, and targeted therapy while analyzing applications associated with primary peritoneal cancer and secondary peritoneal cancer. The report highlights important industry factors influencing adoption, including technological advancements, healthcare infrastructure improvements, and increasing demand for personalized oncology solutions.

The report coverage also includes evaluation of regional market performance, company strategies, investment trends, and product development activities. The analysis examines competitive developments among leading companies and identifies key opportunities emerging from advancements in cancer treatment technologies. The report provides insights into market dynamics, including major drivers, restraints, opportunities, and challenges affecting industry growth between 2026 and 2035. It supports stakeholders in understanding evolving treatment trends, technological innovation, and strategic opportunities within the global peritoneal cancer treatment ecosystem.